Development And Validation Of A Gene Expression Assay To Predict The Risk Of Recurrence Disease In Cutaneous Squamous Cell Carcinoma
Principal Investigator(s)
Email for information
Funded by
GENEVA
Research Start Date
Status
Active
This multicenter study will evaluate up to 860 archived primary Cutaneous Squamous Cell Carcinoma (cSCC) tumor samples diagnosed after 2006, with or without documented local or regional recurrence of disease, with a minimum of 3 years follow up data (for patients with no known recurrence) in the signature development phase and up to 2000 patients in the validation phase. Archived primary cSCC tissue samples from study site specimen storage facilities will be analyzed.
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.